GlassScriptPhysician profile
Amie Briggs
NPI 1093081978
$4,173.78
in general payments reported to CMS, 2019-2025
33 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $868 · 2022: $374 · 2023: $874 · 2024: $1,025 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.16 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,371.03 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Neurelis, INC. | $534.39 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $429.42 | 2022-2025 | |
| Eisai INC. | $261.52 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.71 | 2021-2025 | Eohilia |
| Azurity Pharmaceuticals, INC. | $148.01 | 2022-2025 | Triptodur, Zonisade |
| Regeneron Healthcare Solutions, INC. | $143.98 | 2022-2024 | Dupixent |
| Abbvie INC. | $132.03 | 2021-2025 | |
| Genzyme Corporation | $128.07 | 2023-2024 | |
| Dexcom, INC. | $119.63 | 2021-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $102.06 | 2021-2025 | Qelbree |
| Xeris Pharmaceuticals, INC. | $87.98 | 2021-2023 | Gvoke Hypopen |
| Aucta Pharmaceuticals, INC. | $74.89 | 2025 | Motpoly Xr |
| Upsher-Smith Laboratories LLC | $50.38 | 2025 | |
| Zealand Pharma US, INC. | $49.20 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $39.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.91 | 2021 | |
| Zogenix INC. | $29.80 | 2021 | |
| Nestle Healthcare Nutrition INC. | $29.09 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $26.27 | 2025 | Daybue |
| Biocodex, INC. | $22.87 | 2024 | |
| Medtronic, INC. | $21.29 | 2021 | |
| Lundbeck LLC | $20.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.26 | 2021 | |
| Biogen, INC. | $19.94 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.27 | 2023 | Dysport |
| Lilly USA, LLC | $16.97 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $16.31 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.08 | 2022 | |
| Abbott Laboratories | $14.66 | 2021 | |
| Ptc Therapeutics, INC. | $14.20 | 2021 | |
| Travere Therapeutics, INC. | $13.40 | 2023 | Cholbam |
| Eton Pharmaceuticals, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.